Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy.
Bhagavan HN, Chopra RK. Clin Nutr. Jun 2005;24(3):331-338.

Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders.
Marriage BJ, Clandinin MT, Macdonald IM, Glerum DM. Mol Genet Metab. Apr 2004;81(4):263-272.

The expanding phenotype of mitochondrial myopathy.
DiMauro S, Gurgel-Giannetti J. Curr Opin Neurol. Oct 2005;18(5):538-542.

Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.
Beal MF. J Bioenerg Biomembr. Aug 2004;36(4):381-386.

Coenzyme Q10 serum levels in Huntington's disease.
Andrich J, Saft C, Gerlach M, et al. J Neural Transm Suppl. 2004(68):111-116.

Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy.
Ogasahara S, Engel AG, Frens D, Mack D. Proc Natl Acad Sci U S A. Apr 1989;86(7):2379-2382.

Efficacy of coenzyme Q10 for improved tolerability of cancer treatments: a systematic review.
Roffe L, Schmidt K, Ernst E. J Clin Oncol. Nov 1 2004;22(21):4418-4424.

Considerations for supplementing with coenzyme Q10 during statin therapy.
Levy HB, Kohlhaas HK. Ann Pharmacother. Feb 2006;40(2):290-294.

Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
Ferrante KL, Shefner J, Zhang H, et al. Neurology. Dec 13 2005;65(11):1834-1836.